Management of Asymptomatic Patient Exposed to Spouse with Active TB

Immediate Assessment and Treatment

The American Thoracic Society recommends immediately initiating treatment for latent tuberculosis infection (LTBI) in household contacts, regardless of tuberculin skin test (TST) or interferon-gamma release assay (IGRA) results, after excluding active TB disease 1
A chest radiograph (posterior-anterior view) should be obtained to rule out active pulmonary TB before starting any LTBI treatment, as recommended by the Centers for Disease Control and Prevention 1
The patient should be assessed for TB symptoms, including persistent cough, weight loss, night sweats, bloody sputum, fever, or anorexia, as suggested by the MMWR Recommendations and Reports 2, 1

The American College of Chest Physicians recommends 9 months of daily isoniazid (5 mg/kg, maximum 300 mg daily) as the most extensively studied regimen for LTBI treatment 5, 1
A shorter regimen of 3-4 months of daily isoniazid plus rifampin (isoniazid 5 mg/kg max 300 mg + rifampin 10 mg/kg max 600 mg) is also recommended by the European Respiratory Society as a shorter duration with similar efficacy 6, 1

The Centers for Disease Control and Prevention recommend obtaining baseline AST/ALT and bilirubin if the patient has HIV infection, history of chronic liver disease, regular alcohol use, pregnancy or within 3 months postpartum, or concurrent use of other hepatotoxic medications 7
Baseline testing is not routinely required for otherwise healthy adults, as stated by the MMWR Recommendations and Reports 7

The patient should be scheduled for monthly visits to assess adherence and monitor for adverse effects, and educated about hepatotoxicity symptoms, as recommended by the Praxis Medical Insights 1, 4
Routine monthly laboratory monitoring is not required for patients with normal baseline tests and no risk factors, but liver function tests should be performed if symptoms of hepatotoxicity develop, as suggested by the MMWR Recommendations and Reports 7

For HIV-positive patients, treatment for LTBI is critical, as HIV infection increases TB reactivation risk, and a TST reaction ≥5 mm is considered positive, as recommended by the Clinical Infectious Diseases 5, 4
Baseline and ongoing laboratory monitoring is mandatory for HIV-positive patients, and drug interactions should be considered if the patient is on antiretroviral therapy, particularly with rifampin-containing regimens, as stated by the MMWR Recommendations and Reports 7, 8